PET/CT in the Evaluation of Inflammatory Bowel Disease: Studies in Patients Before and After Treatment
- First Online:
- Cite this article as:
- Spier, B.J., Perlman, S.B., Jaskowiak, C.J. et al. Mol Imaging Biol (2010) 12: 85. doi:10.1007/s11307-009-0232-1
- 210 Downloads
The purpose of this study was to evaluate the appropriate 2-deoxy-2-[18F]fluoro-d-glucose–positron emission tomography (FDG-PET) determination in patients with inflammatory bowel disease (IBD) before and after clinical improvement to see if this determination correlates with clinical activity.
We performed PET–computed tomography (PET/CT) on five patients before and after successful medical therapy in patients with moderately active IBD. Each patient had five bowel segments scored (0–3) for the appropriate FDG-PET determination.
There were five patients [Crohn’s disease (CD) = 3, ulcerative colitis = 2] who were studied an average of 437 days (range, 77–807) after initial PET/CT scan. All patients showed significant improvement in physician global assessment scores (p = 0.004) and underwent repeat PET/CT. The total score of all segments was 32 pretreatment and 14 posttreatment (p < 0.01). Of 11 pretreatment active segments, nine (82%) segments either became inactive or displayed decreased activity, while two showed no change (p < 0.001).
Appropriate FDG-PET determination decreases with successful treatment of inflammation in active IBD and correlates with symptom improvement.